Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter and Nine Months ended December 31, 2017
Currency: Indian Rupees (Rs.) with U.S. Dollar (U.S.$) convenience translation at Rs. 63.83 = U.S.$1.00
Business Overview: DRL is a leading India-based pharmaceutical company operating through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company manufactures and markets prescription and over-the-counter pharmaceuticals, active pharmaceutical ingredients (APIs), and differentiated formulations globally.
Key Financial Metrics
For the Nine Months Ended December 31, 2017 (in millions, unless noted):
- Revenues: Rs. 106,679 (U.S.$ 1,671)
- Gross Profit: Rs. 57,409 (53.8% margin)
- Operating Profit: Rs. 9,270 (8.7% margin)
- Profit Before Tax: Rs. 10,593
- Net Profit: Rs. 6,784 (U.S.$ 106)
- Earnings Per Share (Basic): Rs. 40.91 (U.S.$ 0.64)
- Net Cash from Operating Activities: Rs. 12,248 (U.S.$ 192)
- Net Cash Used in Investing Activities: Rs. (15,680) (U.S.$ (246))
- Net Cash from Financing Activities: Rs. 1,597 (U.S.$ 25)
- Cash and Cash Equivalents (Dec 31, 2017): Rs. 2,010 (U.S.$ 31)
- Total Debt (Short-term + Long-term): Rs. 54,786 (Short-term: Rs. 30,301; Long-term: Rs. 24,461)
Material Changes vs. Prior Period
Revenue: Consolidated revenues increased 1% to Rs. 106,679 million for the nine months ended Dec 31, 2017, compared to Rs. 105,267 million in the prior year. This growth was driven by the Proprietary Products segment (+88%), largely due to a one-time milestone payment, while Global Generics remained flat and PSAI declined slightly (-1%).
Profitability: Net profit decreased 24% to Rs. 6,784 million from Rs. 8,914 million in the prior year. Gross margin declined from 57.2% to 53.8%, primarily due to price erosion in key markets (North America) and a shift in product mix toward lower-margin products.
Tax Expense: The effective tax rate increased significantly to 36.0% (from 22.2% in the prior year). This was primarily due to a one-time charge of Rs. 930 million resulting from the re-measurement of U.S. deferred tax assets and liabilities following the enactment of the U.S. Tax Cuts and Jobs Act of 2017.
Segment Performance:
- Global Generics: Revenues flat; North America revenues decreased 6% (4% in constant currency) due to price erosion, partially offset by new product launches.
- Proprietary Products: Revenues surged 88% due to a U.S.$20 million milestone payment for Impoyz (clobetasol propionate) cream.
- PSAI: Revenues declined 1% due to decreased orders for pharmaceutical development services, offset by increased API sales volumes.
Guidance, Outlook, Risks, and Unusual Items
Unusual Items:
- U.S. Tax Reform: A one-time non-cash charge of Rs. 930 million impacted the Q4 2017 tax provision.
- Milestone Revenue: Recognition of U.S.$20 million (Rs. 1,300 million) from the Impoyz approval in the Proprietary Products segment.
- Legal Settlement: Accrual of Rs. 319 million for a settlement with the U.S. Department of Justice regarding child-resistant packaging litigation.
Risks and Contingencies:
- Regulatory Actions: The company received a warning letter from the U.S. FDA in 2015 regarding cGMP deviations at Indian facilities. While re-inspections in 2017 identified new observations, the Miryalaguda API facility inspection was closed in June 2017. A German regulatory authority temporarily suspended GMP certification for the Bachupally facility in August 2017, but this was resolved in January 2018.
- Price Control Litigation: Ongoing disputes with India's National Pharmaceutical Pricing Authority (NPPA) regarding price caps on cardiovascular and anti-diabetic formulations. The company has accrued Rs. 406 million for potential liabilities.
- Venezuela Operations: Continued foreign exchange losses due to currency devaluation and restrictions on repatriating funds. No revenues were earned from Venezuela in the current period.
- Antitrust Litigation: The company is a defendant in various U.S. antitrust class actions regarding generic drug pricing (e.g., Nexium, Namenda, and multi-district litigation involving zoledronic acid and meprobamate). The company denies wrongdoing and believes liability is not probable.
Outlook: Management continues to focus on building a pipeline of complex generics, biosimilars, and differentiated products. The company expects to resolve outstanding regulatory observations in a timely manner.
Key Facts for Investor Verification
- Impact of U.S. Tax Law: Verify the long-term impact of the U.S. Tax Cuts and Jobs Act on future effective tax rates and deferred tax asset valuations.
- Regulatory Status: Confirm the status of U.S. FDA and EU regulatory inspections, specifically regarding the Miryalaguda, Srikakulam, and Duvvada facilities, and the potential for future product shipment restrictions.
- Price Erosion Trends: Monitor the trajectory of price erosion in the North American generics market and its effect on gross margins.
- Legal Accruals: Review the sufficiency of provisions for NPPA price control disputes and ongoing U.S. antitrust litigation.
- Debt Structure: Note the refinancing of short-term borrowings into long-term debt (Swiss and German subsidiaries) and the associated interest rate profiles (LIBOR-based).